In the new 2022 ESC guidelines on cardiovascular assessment and management in patients undergoing non-cardiac surgery, the measurement of NT-proBNP has a Class IIa recommendation for application in patients with known cardiovascular disease, cardiovascular risk factors, or symptoms suggestive of cardiovascular disease undergoing non-cardiac surgery with intermediate or high surgical risk [6]. This evidence concerns the gene NPPB and cardiovascular disorder.